Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 264 results for "Tecfidera Treated Patients"

New treatment strategies and evidence from clinical trials ...

Upcoming SlideShare Loading in … 5 1. IMPROVING THE PATIENTS LIFE THROUGH MEDICAL EDUCATION Reshaping the immune system in multiple sclerosis: a sustainable goal? 24 November 2016 - Baveno, Italy 2. New treatment strategies ..., 1 week ago

1 images for "Tecfidera Treated Patients"

European Pharmaceutical Review, 7 months ago

Combination Strategy to Attack Multiple Sclerosis

Home » Health » / no comments Actelion Ltd. is seeking more effective treatments for people suffering from multiple sclerosis by following a strategy that's worked in treating HIV, cancer and heart failure — combining medicines to ...
 HealthMediciNet.com1 month ago Actelion Using Combination Strategy to Attack Multiple Sclerosis  Bloomberg1 month ago Reconsidering the Economic Value of Multiple Sclerosis Therapies  American Journal of Managed Care1 month ago

Roche's Ocrelizumab Expected To Introduce Major Shifts In The Treatment Paradigm For Multiple Sclerosis

By a News Reporter-Staff News Editor at Biotech Week There is high anticipation for Roche's ocrelizumab, a monoclonal antibody that was granted "Breakthrough Therapy Designation" by the FDA earlier this year for its potential indication in treating ...
 Pharmacy Choice1 month ago
Frontiers in Neurorobotics

Activated IL-1RI Signaling Pathway Induces Th17 Cell Differentiation via Interferon Regulatory Factor 4 Signaling in Patients with Relapsing-Remitting Multiple Sclerosis

Introduction IL-1β induces differentiation of T helper (Th) 17 cells, which play a critical role in the development of the autoimmune response. IL-1β contributes to IL-6-induced RORc expression and IL-17A production in humans ( 1 , 2 ), ...
 Frontiers in Neurorobotics4 days ago

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline December 23, 2016

/ Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain of its officers. The class action is on behalf of a class consisting of all ...
 International Business Times1 day ago Biogen Inc : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline December 23, 2016  4 Traders1 day ago EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm  International Business Times1 week ago SHAREHOLDER ALERT Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline - December 23, 2016  Nation's Restaurant News4 days ago

What's Wrong With Pharma Stocks May Last A While, But...

Introduction As many of you know, Eli Lilly (NYSE: LLY ) has announced unimpressive results of a highly-awaited clinical trial in Alzheimer's disease. These weak results join numerous industry disappointments. This article reviews some of these, ...
 Seeking Alpha1 week ago

Huge Increase in Number of Doctors Annually Prescribing Millions of Dollars Worth of Medicare Prescriptions

By Charles Ornstein and Ryann Grochowski Jones, ProPublica The number of doctors who each prescribe millions of dollars of medications annually in Medicare 's drug program has soared, driven by expensive hepatitis C treatments and rising drug ...
 AllGov1 week ago High-dollar prescribers proliferate in Medicare's drug program  UPI2 weeks ago A Growing Group Of Doctors Are Big-Money Prescribers In Medicare  NPR2 weeks ago

3 Beaten-Down Biotech Stocks to Buy for Huge Gains

In addition to financial stocks, the healthcare sector and biotech stocks breathed a collective sigh of relief following the election of Donald Trump as President. It is widely believed that a secular trend of increased regulation on these ...
 Nasdaq2 weeks ago

Secrets of a successful launch? Ask Gilead, Biogen and J&J

Drugmakers spend billions on R&D every year, hoping to createa drug that can throw a commercial punch. It's never perfectly clear which projects will reach the market, much less deliver big sales, but a new report offers some clues. In its first ...
 FiercePharma2 weeks ago

Better Buy: Biogen Inc. vs. Celgene Corporation

This year might have started off poorly for biotech stocks, but things have certainly changed after the surprising election results. Two of the biggest biotechs around, Biogen (NASDAQ: BIIB) and Celgene (NASDAQ: CELG), are now enjoying nice runs.
 FOXBusiness.com2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less